Adverse effects with long-term cyclosporin for severe psoriasis.
The use of cyclosporin A (CSA) for the treatment of severe psoriasis is well established. However its use is limited by its adverse effects, especially nephrotoxicity. We reviewed 28 patients treated with CSA for severe psoriasis over an 11-year period. All patients were on long-term CSA treatment (median duration 55.5 months). Twenty patients developed renal impairment which required discontinuation of treatment in seven. Twelve patients' renal function stabilized on dose reduction and one improved. Sixteen patients developed hypertension. For this small group of patients with severe psoriasis, recalcitrant to other treatments, CSA afforded better quality of life which they otherwise could not enjoy. Although this comes at a cost with the development of renal impairment we feel that such patients can be continued on CSA provided that they are under the combined care of a dermatologist and a nephrologist.
Markham
Trevor
T
Department of Dermatology, City of Dublin Skin and Cancer Hospital, St. Vincent's University Hospital, Dublin, Ireland. trevormarkham@hotmail.com
Watson
A
A
Rogers
S
S
D058186:Acute Kidney Injury / Q000139:chemically induced; D000328:Adult; D000368:Aged; D017281:Cost of Illness; D016572:Cyclosporine / Q000009:adverse effects*; D003879:Dermatologic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D012189:Retrospective Studies
D003879:Dermatologic Agents; D016572:Cyclosporine